Dohil et al., 2010 - Google Patents
Oral viscous budesonide is effective in children with eosinophilic esophagitis in a randomized, placebo-controlled trialDohil et al., 2010
View HTML- Document ID
- 9237405637138225337
- Author
- Dohil R
- Newbury R
- Fox L
- Bastian J
- Aceves S
- Publication year
- Publication venue
- Gastroenterology
External Links
Snippet
BACKGROUND & AIMS: Eosinophilic esophagitis (EoE) is caused by immunologic reactions to ingested/inhaled allergens. The diagnosis is considered if≥ 15 eosinophils per high- powered field (eos/hpf) are detected in mucosal biopsies. Placebo-controlled studies have …
- 206010064212 Eosinophilic oesophagitis 0 title abstract description 73
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane, progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Dohil et al. | Oral viscous budesonide is effective in children with eosinophilic esophagitis in a randomized, placebo-controlled trial | |
| Facchin et al. | Microbiota changes induced by microencapsulated sodium butyrate in patients with inflammatory bowel disease | |
| Reed et al. | Eosinophilic esophagitis | |
| Visaggi et al. | Eosinophilic esophagitis: clinical, endoscopic, histologic and therapeutic differences and similarities between children and adults | |
| Peterson et al. | Comparison of esomeprazole to aerosolized, swallowed fluticasone for eosinophilic esophagitis | |
| Dellon et al. | Advances in clinical management of eosinophilic esophagitis | |
| Schaefer et al. | Comparison of oral prednisone and topical fluticasone in the treatment of eosinophilic esophagitis: a randomized trial in children | |
| Dellon | Diagnosis and management of eosinophilic esophagitis | |
| Poropat et al. | Enteral nutrition formulations for acute pancreatitis | |
| Gupta et al. | Efficacy and safety of oral budesonide suspension in pediatric patients with eosinophilic esophagitis | |
| Świerczyńska-Krępa et al. | Aspirin desensitization in patients with aspirin-induced and aspirin-tolerant asthma: a double-blind study | |
| Furuta et al. | Eosinophilic esophagitis | |
| Straumann et al. | Update on basic and clinical aspects of eosinophilic oesophagitis | |
| Savarino et al. | The GerdQ questionnaire and high resolution manometry support the hypothesis that proton pump inhibitor‐responsive oesophageal eosinophilia is a GERD‐related phenomenon | |
| Kavitt et al. | Diagnosis and treatment of eosinophilic esophagitis in adults | |
| Akobeng | Crohn’s disease: current treatment options | |
| Leclere et al. | Efficacy of oral prednisolone and dexamethasone in horses with recurrent airway obstruction in the presence of continuous antigen exposure | |
| BR112020004964A2 (en) | method consisting of administering an effective amount of tradipitant, enhancement, improved method for treating a patient suffering from atopic itching or dermatitis with tradipitant, and methods for treating a patient with itching or atopic dermatitis, for selecting and determining a dosage of effective tradipitant, to determine that a patient is likely to respond to treatment of atopic dermatitis with tradipitant and to identify a patient. | |
| de Bortoli et al. | The 1st EoETALY Consensus on the Diagnosis and Management of Eosinophilic Esophagitis–Current Treatment and Monitoring | |
| Mari et al. | Eosinophilic esophagitis in adults: a concise overview of an evolving disease | |
| Massironi et al. | Eosinophilic esophagitis: does age matter? | |
| Aceves et al. | Integrated approach to treatment of children and adults with eosinophilic esophagitis | |
| Sharma | Disulfiram and low nickel diet in the management of hand eczema: a clinical study | |
| Visaggi et al. | Optimal assessment, treatment, and monitoring of adults with eosinophilic esophagitis: strategies to improve outcomes | |
| Fernandez-Becker | Eosinophilic esophagitis: incidence, diagnosis, management, and future directions |